Loss of ZNF516 protein expression is related with HR-HPV infection and cervical preneoplastic lesions
- 28 Downloads
Cervical cancer is an important health issue among women worldwide. Cervical smear and human papillomavirus detection are the most used screening methods to detect preneoplastic and neoplastic lesions. However, as neither can predict cervical development, new markers are needed for this disease. ZNF516, a potential tumor suppressor gene, has been found altered in cervical cancer. The objective of this study was to determine ZNF516 immunohistochemistry frequency in cervical biopsies and its association with clinicopathological parameters, to evaluate its potential as marker in cervical lesions.
A retrospective series of 452 formalin-fixed, paraffin-embedded (FFPE) cervical biopsies, obtained between 2002 and 2007, were selected for immunohistochemistry of ZNF516, p16 and Ki-67 markers. Human papillomavirus genotyping was performed on 272 of these samples through reverse line blot assay.
An inverse relation between ZNF516 expression and cervical lesions grade (P < 0.001) was observed, given this protein was found mainly expressed in normal tissues, while was decreased in cervical lesions. As expected, the proliferation markers p16 and Ki-67 were found highly expressed in cervical cancer compared to normal tissues, and inversely correlated to ZNF516 expression (P < 0.01). High oncogenic risk-Human papillomavirus presence also was related to the lack of ZNF516 expression in cervical lesions (P < 0.05), and the detection of these two parameters showed a high sensitivity (70.9%) for preneoplastic lesions detection.
The loss of ZNF516 expression was found in cervical lesions, and its detection potentially could be used as a complementary marker of early diagnosis in cervical lesions.
KeywordsZNF516 Cervical cancer Immunohistochemistry p16 Ki-67 Human papillomavirus
Fondo Nacional de Desarrollo Científico y Tecnológico de Chile (FONDECYT) nos. 3130630, 11150622, 11150802, 3180550 and 3170826; Fondo de Financiamiento de Centros de Investigación en Áreas Prioritarias no. 15130011; The Millennium Institute on Immunology and Immunotherapy no. P09-016-F.
Protocol/project development, data collection or management, data analysis and manuscript writing/editing. CI: project development, data management, data analysis and Manuscript writing. JL: protocol development, data collection and manuscript editing. KB: data analysis and manuscript editing. IR: data analysis and manuscript editing. JR: data collection and manuscript editing. LZ: data analysis and manuscript editing. BM: data collection and manuscript editing. CV: data collection and manuscript editing. JCR: data collection and management and manuscript. PB: project development, data management, data analysis and manuscript writing editing.
Compliance with ethical standards
Conflict of interest
The authors declare that they have no conflict of interest.
All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. This research is a retrospective study including biopsy tissue samples of archive. Therefore, for this type of study formal consent is not required. The use of these samples was approved by the ethical scientific committee of School of Medicine (Document no. 17/012), Universidad de La Frontera, Temuco, Chile.
This research is a retrospective study including biopsy tissue samples of archive. Therefore, for this study informed consent was not obtained. The use of these samples was approved by the ethical scientific committee of School of Medicine (Document no. 17/012), Universidad de La Frontera, Temuco, Chile.
- 8.Darragh TM, Colgan TJ, Cox JT et al (2012) The Lower Anogenital Squamous Terminology Standardization Project for HPV-associated lesions: background and consensus recommendations from the College of American Pathologists and the American Society for Colposcopy and Cervical Pathology. Arch Pathol Lab Med 136:1266–1297. https://doi.org/10.5858/arpa.LGT200570 CrossRefPubMedGoogle Scholar
- 12.Brebi P, Maldonado L, Noordhuis MG et al (2014) Genome-wide methylation profiling reveals Zinc finger protein 516 (ZNF516) and FK-506-binding protein 6 (FKBP6) promoters frequently methylated in cervical neoplasia, associated with HPV status and ethnicity in a Chilean population. Epigenetics 9:308–317. https://doi.org/10.4161/epi.27120 CrossRefPubMedGoogle Scholar
- 13.Guerrero-Preston R, Valle BL, Jedlicka A et al (2016) Molecular Triage of premalignant lesions in liquid-based cervical cytology and circulating cell-free DNA from urine, using a panel of methylated human papilloma virus and host genes. Cancer Prev Res 9:915–924. https://doi.org/10.1158/1940-6207.CAPR-16-0138 CrossRefGoogle Scholar
- 20.van Baars R, Griffin H, Wu Z et al (2015) Investigating diagnostic problems of CIN1 and CIN2 associated with high-risk HPV by combining the novel molecular biomarker PanHPVE4 with P16INK4a. Am J Surg Pathol 39:1518–1528. https://doi.org/10.1097/PAS.0000000000000498 CrossRefPubMedPubMedCentralGoogle Scholar
- 25.Santos ALF, Derchain SFM, Sarian LO et al (2006) Performance of Pap smear and human papilloma virus testing in the follow-up of women with cervical intraepithelial neoplasia grade 1 managed conservatively. Acta Obstet Gynecol Scand 85:444–450. https://doi.org/10.1080/00016340600604682 CrossRefPubMedGoogle Scholar